FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017962877> ?p ?o ?g. }

• W3017962877 endingPage "872" @default.
• W3017962877 startingPage "866" @default.
• W3017962877 abstract "Abstract Data on direct‐acting antiviral agent (DAA) treatment for mixed genotype hepatitis C virus (HCV) infection are scant. This study examined the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) and ledipasvir/sofosbuvir (LDV/SOF) for mixed HCV genotype infection in a real‐world setting in Taiwan. We analysed the data from all patients with mixed HCV genotype infections treated with GLE/PIB or LDV/SOF from 2017 to 2019 in three Chang Gung Memorial Hospitals in Taiwan. The primary treatment outcome was sustained virologic response 12 weeks after treatment cessation (SVR12). Adverse events (AEs) were also evaluated. A total of 5190 HCV patients received DAA treatment during this time period. Among them, 116 patients (2.2%) had mixed infections of any 2 or 3 genotypes of 1a, 1b, 2, 3 and 6. Fifty‐four patients received GLE/PIB and 62 received LDV/SOF. SVR12 rates for LDV/SOF vs GLE/PIB therapy were 96.6% (56/58) vs 100% (51/51) by the per‐protocol analysis and 90.3% (56/62) vs 94.4% (51/54) by the evaluable population analysis. Two patients with 1b + 6 and 1b + 2 genotype infections in the LDV/SOF group had relapse. Evaluating the GLE/PIB vs LDV/SOF groups for the most common AEs revealed pruritus (16.7% vs 4.8%), abdominal discomfort (5.6% vs 8%) and fatigue (5.6% vs 4.8%). One patient with AE‐related treatment discontinuation presented with liver decompensation after 4‐week GLE/PIB therapy. DAA‐related significant laboratory abnormalities occurred in two patients with >3× elevated bilirubin level in the GLE/PIB group. GLE/PIB and LDV/SOF are well tolerated and achieve high SVR12 rates for patients with mixed HCV genotype infection." @default.
• W3017962877 created "2020-05-01" @default.
• W3017962877 creator A5005080716 @default.
• W3017962877 creator A5008054592 @default.
• W3017962877 creator A5016683607 @default.
• W3017962877 creator A5018659248 @default.
• W3017962877 creator A5021453806 @default.
• W3017962877 creator A5027629838 @default.
• W3017962877 creator A5029235954 @default.
• W3017962877 creator A5057490544 @default.
• W3017962877 creator A5059995303 @default.
• W3017962877 creator A5070971869 @default.
• W3017962877 creator A5086810877 @default.
• W3017962877 creator A5087116882 @default.
• W3017962877 date "2020-05-12" @default.
• W3017962877 modified "2023-10-18" @default.
• W3017962877 title "Real‐world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan" @default.
• W3017962877 cites W1967115110 @default.
• W3017962877 cites W1975184667 @default.
• W3017962877 cites W1986686301 @default.
• W3017962877 cites W1994600915 @default.
• W3017962877 cites W2013143961 @default.
• W3017962877 cites W2042063943 @default.
• W3017962877 cites W2055154062 @default.
• W3017962877 cites W2066168379 @default.
• W3017962877 cites W2086388926 @default.
• W3017962877 cites W2096347191 @default.
• W3017962877 cites W2110633314 @default.
• W3017962877 cites W2185218296 @default.
• W3017962877 cites W2560002598 @default.
• W3017962877 cites W2578013986 @default.
• W3017962877 cites W2602169852 @default.
• W3017962877 cites W2747173759 @default.
• W3017962877 cites W2769512910 @default.
• W3017962877 cites W2771838944 @default.
• W3017962877 cites W2781547231 @default.
• W3017962877 cites W2789669413 @default.
• W3017962877 cites W2890778396 @default.
• W3017962877 cites W2909208367 @default.
• W3017962877 cites W2920923774 @default.
• W3017962877 cites W2954997469 @default.
• W3017962877 cites W2968677045 @default.
• W3017962877 doi "https://doi.org/10.1111/jvh.13305" @default.
• W3017962877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32343472" @default.
• W3017962877 hasPublicationYear "2020" @default.
• W3017962877 type Work @default.
• W3017962877 sameAs 3017962877 @default.
• W3017962877 citedByCount "7" @default.
• W3017962877 countsByYear W30179628772021 @default.
• W3017962877 countsByYear W30179628772022 @default.
• W3017962877 crossrefType "journal-article" @default.
• W3017962877 hasAuthorship W3017962877A5005080716 @default.
• W3017962877 hasAuthorship W3017962877A5008054592 @default.
• W3017962877 hasAuthorship W3017962877A5016683607 @default.
• W3017962877 hasAuthorship W3017962877A5018659248 @default.
• W3017962877 hasAuthorship W3017962877A5021453806 @default.
• W3017962877 hasAuthorship W3017962877A5027629838 @default.
• W3017962877 hasAuthorship W3017962877A5029235954 @default.
• W3017962877 hasAuthorship W3017962877A5057490544 @default.
• W3017962877 hasAuthorship W3017962877A5059995303 @default.
• W3017962877 hasAuthorship W3017962877A5070971869 @default.
• W3017962877 hasAuthorship W3017962877A5086810877 @default.
• W3017962877 hasAuthorship W3017962877A5087116882 @default.
• W3017962877 hasConcept C104317684 @default.
• W3017962877 hasConcept C126322002 @default.
• W3017962877 hasConcept C135763542 @default.
• W3017962877 hasConcept C159047783 @default.
• W3017962877 hasConcept C197934379 @default.
• W3017962877 hasConcept C2522874641 @default.
• W3017962877 hasConcept C2775999097 @default.
• W3017962877 hasConcept C2776408679 @default.
• W3017962877 hasConcept C2776455275 @default.
• W3017962877 hasConcept C2778390639 @default.
• W3017962877 hasConcept C2778715236 @default.
• W3017962877 hasConcept C2780040827 @default.
• W3017962877 hasConcept C2908647359 @default.
• W3017962877 hasConcept C55493867 @default.
• W3017962877 hasConcept C71924100 @default.
• W3017962877 hasConcept C86803240 @default.
• W3017962877 hasConcept C90924648 @default.
• W3017962877 hasConcept C99454951 @default.
• W3017962877 hasConceptScore W3017962877C104317684 @default.
• W3017962877 hasConceptScore W3017962877C126322002 @default.
• W3017962877 hasConceptScore W3017962877C135763542 @default.
• W3017962877 hasConceptScore W3017962877C159047783 @default.
• W3017962877 hasConceptScore W3017962877C197934379 @default.
• W3017962877 hasConceptScore W3017962877C2522874641 @default.
• W3017962877 hasConceptScore W3017962877C2775999097 @default.
• W3017962877 hasConceptScore W3017962877C2776408679 @default.
• W3017962877 hasConceptScore W3017962877C2776455275 @default.
• W3017962877 hasConceptScore W3017962877C2778390639 @default.
• W3017962877 hasConceptScore W3017962877C2778715236 @default.
• W3017962877 hasConceptScore W3017962877C2780040827 @default.
• W3017962877 hasConceptScore W3017962877C2908647359 @default.
• W3017962877 hasConceptScore W3017962877C55493867 @default.
• W3017962877 hasConceptScore W3017962877C71924100 @default.
• W3017962877 hasConceptScore W3017962877C86803240 @default.
• W3017962877 hasConceptScore W3017962877C90924648 @default.

• next